Saturday 17 October 2026
Export ZYME’s income statement to Excel — free account
Zymeworks Inc.
ZYME Healthcare Biotechnology
Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024. In the quarter to June 2026, revenue fell 90.6%, EPS fell 2,166.7% and free cash flow fell 385.5%, each against the same quarter a year earlier.
25.07
0.68
−2.64%
Follow ZYME
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | 7 | 4 | 2 | 4 | 2 | 8 | 3 | 4 | 7 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.24 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | 5.95 | 3.79 | 6.83 | 9.64 | 0.07 | 2.90 | 2.15 | 2.59 | 11.56 |
P/S ratio |
15.62 | 3.26 | 8.05 | 58.51 | 61.13 | 31.67 | 1.19 | 9.40 | 14.55 | 18.74 |
P/FCF ratio |
0.00 | 0.00 | 20.57 | 0.00 | 0.00 | 0.00 | 3.75 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(1.28) | 8.59 | 4.79 | 0.86 | 2.66 | (3.93) | 6.41 | 2.84 | (1.97) | (3.24) |
Beneish M-Score |
— | (7.25) | — | — | — | — | 2.12 | — | — | — |
P/Operating CF |
(13.50) | 4.32 | 8.52 | (47.55) | (49.71) | (16.73) | 1.50 | 51.23 | (26.75) | (193.53) |
P/B ratio |
0.00 | 1.45 | 2.37 | 7.04 | 5.81 | 3.39 | 1.00 | 1.54 | 3.28 | 7.39 |
Price to Tangible BV |
0.00 | 1.63 | 2.56 | 7.59 | 6.06 | 3.62 | 1.04 | 1.61 | 3.45 | 7.78 |
EV/Sales |
13.59 | 1.65 | 4.36 | 48.58 | 50.34 | 23.37 | 0.06 | 4.78 | 11.89 | 16.58 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.18 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(3.64) | 389.16 | 9.57 | (17.53) | (12.95) | (3.24) | 0.17 | (3.07) | (8.24) | (53.23) |
EV/FCF |
(3.16) | (29.37) | 11.15 | (14.61) | (12.44) | (3.03) | 0.18 | (2.89) | (8.02) | (49.69) |
Quick Ratio |
2.69 | 6.15 | 6.69 | 3.65 | 5.16 | 3.73 | 5.50 | 7.06 | 3.19 | 5.52 |
Current Ratio |
2.81 | 6.30 | 6.82 | 3.78 | 5.31 | 4.01 | 5.70 | 7.41 | 3.40 | 5.88 |
Net Debt/EBITDA |
0.97 | 14.03 | 6.73 | 2.08 | 2.41 | 1.23 | (3.57) | 3.10 | 1.79 | 2.81 |
Debt/Assets |
4.70% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.19 | 0.46 | 0.28 | 0.10 | 0.09 | 0.06 | 0.79 | 0.12 | 0.15 | 0.26 |
Operating CF/Net income |
1.04 | (0.02) | (0.66) | 0.56 | 0.84 | 0.91 | 1.16 | 1.00 | 0.90 | 0.41 |
Capex/Depreciation |
(5.33) | (1.14) | (0.94) | (1.89) | (0.61) | (1.39) | (1.81) | (0.24) | (0.27) | (0.21) |
Interest Coverage |
(39.86) | (21.32) | (9.12) | (25.12) | (32.91) | (109.74) | 36.30 | — | — | — |
| (248.22%) | (17.42%) | (24.62%) | (68.25%) | (55.08%) | (64.29%) | 33.51% | (24.78%) | (30.54%) | (26.72%) | |
| (57.72%) | (9.67%) | (19.42%) | (47.48%) | (39.83%) | (45.68%) | 23.96% | (19.30%) | (23.51%) | (20.04%) | |
ROIC |
(73.91%) | (19.64%) | 0.00% | 0.00% | 0.00% | 0.00% | 11,267.96% | (95.36%) | (75.84%) | (145.69%) |
Return on Tangible Assets |
(92.25%) | (12.88%) | (20.21%) | (60.50%) | (47.32%) | (88.58%) | 26.24% | (31.48%) | (53.39%) | (36.55%) |
Average Days of Receivables |
142.80 | 16.43 | 2.46 | 26.99 | 143.31 | 213.61 | 29.56 | 93.53 | 266.99 | 15.98 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
114.03% | 35.84% | 55.56% | 217.23% | 141.76% | 159.52% | 17.78% | 92.68% | 80.61% | 58.05% |
Intangible Assets out of Total Assets |
0.14 | 0.10 | 0.06 | 0.05 | 0.03 | 0.04 | 0.03 | 0.03 | 0.04 | 0.04 |
Share Based Compensation of Revenue |
38.98% | 6.62% | 25.35% | 165.84% | 74.75% | 40.31% | 0.97% | 10.66% | 23.32% | 26.46% |
Graham Net Nets |
0.01 | 0.46 | 0.33 | 0.11 | 0.14 | 0.18 | 0.79 | 0.42 | 0.16 | 0.09 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.40 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(27.92%) | (14.00%) | (9.20%) | (8.10%) | (7.58%) | (25.08%) | 23.61% | (16.67%) | (11.00%) | (4.10%) |
Free Cash Flow Yield |
(27.58%) | (1.72%) | 4.86% | (5.68%) | (6.62%) | (24.35%) | 26.65% | (17.59%) | (10.19%) | (1.78%) |
Revenue per Share |
0.86 | 2.44 | 1.82 | 0.78 | 0.77 | 0.52 | 6.33 | 1.10 | 1.01 | 1.41 |
Operating CF per Share |
(2.77) | 0.01 | 0.83 | (2.15) | (3.01) | (3.73) | 2.21 | (1.72) | (1.45) | (0.44) |
Capex per Share |
(0.43) | (0.15) | (0.12) | (0.36) | (0.12) | (0.26) | (0.20) | (0.06) | (0.04) | (0.03) |
Free Cash Flow per Share |
(3.20) | (0.14) | 0.71 | (2.52) | (3.13) | (3.99) | 2.01 | (1.78) | (1.49) | (0.47) |
Cash per Share |
3.16 | 4.13 | 6.88 | 7.86 | 8.46 | 4.90 | 7.55 | 5.44 | 2.98 | 3.03 |
Shareholders Equity per Share |
5.33 | 5.48 | 6.20 | 6.46 | 8.14 | 4.83 | 7.56 | 6.75 | 4.47 | 3.56 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
5.33 | 5.48 | 6.20 | 6.46 | 8.14 | 4.83 | 7.56 | 6.75 | 4.47 | 3.56 |
Free Cash Flow |
(40.71) | (2.90) | 20.76 | (95.73) | (157.67) | (205.74) | 130.98 | (122.38) | (113.12) | (35.36) |
Working Capital |
29.93 | 77.67 | 174.38 | 229.28 | 369.41 | 216.37 | 449.08 | 357.16 | 212.16 | 206.45 |
Capital Expenditures |
(5.46) | (3.12) | (3.42) | (13.88) | (6.26) | (13.28) | (13.12) | (4.08) | (3.07) | (2.35) |
Net Current Asset Value |
20.35 | 76.81 | 140.38 | 189.31 | 326.62 | 148.18 | 388.94 | 296.85 | 176.13 | 170.74 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.18 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.50 | 0.06 | 0.06 | 0.47 | 0.16 | 0.50 | 0.03 | 0.05 | 0.04 | 0.02 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.77 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.15 | 0.38 | 0.56 | 0.66 | 0.84 | 0.42 | 0.29 | 0.87 | 0.63 | 0.72 |
Cash ROIC |
(36.17%) | (1.42%) | 5.45% | (17.58%) | (18.85%) | (41.01%) | 13.30% | (14.58%) | (20.04%) | (7.11%) |
Accounts Receivable Turnover |
3.35 | 15.60 | 39.45 | 23.24 | 4.46 | 1.73 | 16.83 | 2.88 | 2.03 | 3.51 |
Accounts Payable Turnover |
5.16 | 4.51 | 5.07 | 4.72 | 4.32 | 3.75 | 2.78 | 2.15 | 2.54 | 2.85 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
93.96 | 79.15 | 85.94 | 112.40 | 93.07 | 114.73 | 153.05 | 116.89 | 162.24 | 96.83 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
3.29 | 3.32 | 1.34 | 1.27 | 8.74 | 15.45 | 24.51 | 26.44 | 37.65 | 30.23 |
Average Payables |
7.13 | 9.27 | 11.23 | 24.55 | 39.67 | 53.22 | 75.13 | 66.73 | 52.92 | 48.09 |
Average Assets |
58.57 | 112.98 | 188.22 | 306.34 | 453.29 | 463.75 | 518.93 | 614.80 | 521.99 | 404.81 |
Average Common Equity |
13.62 | 62.72 | 148.46 | 213.09 | 327.80 | 329.51 | 371.03 | 478.88 | 401.79 | 303.63 |
Columns are period end dates